hotspot -WSS

hotspot

author：explore 2025-10-02 12:01:51 - browse：939

Adam's take main illustration — Molly Ferguson/STAT

Hello! Some takes and thoughts on Gilead’s Trodelvy troubles, Elevation Oncology’s surprising rise, and Kura Oncology’s “wall-crossing” stock sale.

Gilead needs Arcellx more than ever

The clinical trial setback for Trodelvy in non-small cell lung cancer reported by Gilead Sciences on Monday was another dose of bad news for the company’s oncology business. Strategically, does it make sense for Gilead to invest even more in antibody-drug conjugates like Trodelvy, where its lackluster profile and increased competition overall makes winning seem unlikely? Or, should Gilead double down on its Kite division and CAR-T cell therapy — the type of cancer treatments where it truly excels?

If the answers to those questions are no and yes (I lean that way), then Gilead’s current partnership with Arcellx, which is developing a BCMA-targeted CAR-T therapy for multiple myeloma, becomes a lot more important.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： A new study asks: Are we harming blood donors by taking blood?

explore

WSS

Medical mystery: When a cough is not just a cough

Doctors' information doesn't help them choose wisely when sick

Australia's humpback populations rebound raising hopes of marine scientists

4 killed, 7 hurt in mass shooting at July 4 block party in Louisiana; no arrests made

Bacterial infection may be ‘key event’ in endometriosis, study says

Private equity deals in Medicare Advantage declines

hotspot

hotspot

Gilead needs Arcellx more than ever

leisure time

Hollywood unions extend contract negotiations for actors

Russia says it foiled Ukrainian drone attack on Moscow as Kyiv's counteroffensive grinds on

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Biden report: The neurospychology of memory and aging

United colonoscopy coverage change 'may cost lives,' doctors say

Why did Pfizer dish out millions for a Super Bowl ad?

Walensky prepares to leave CDC — and Congress — behind

These geoengineering technologies could help combat the climate crisis, scientists say

Tori Bowie and the unacceptable rates of Black maternal death

Australia's humpback populations rebound raising hopes of marine scientists

entertainment

Australia's humpback populations rebound raising hopes of marine scientists

Grail is spending more than ever lobbying Congress

Doctor appointment wait times are getting worse

Duchenne patients, backed by ‘dark money’ group, to debate drug prices

BioAge raises $170M for combination therapy with Zepbound

Australia's humpback populations rebound raising hopes of marine scientists

explore

Wikipedia

leisure time

focus